![]() |
|
|
Vol. 297, Issue 1, 121-127, April 2001
9-Tetrahydrocannabinol and Morphine
Department of Pharmacology and Toxicology, Virginia Commonwealth
University, Medical College of Virginia Campus, Richmond, Virginia
Recent studies in our laboratory have shown that in mice, low doses of
morphine in combination with
9-tetrahydrocannabinol
(
9-THC) have a similar antinociceptive effect to high
doses of morphine alone. After short-term administration of this
combination, there is no behavioral tolerance to the opioid. Previous
binding studies and Western analyses following chronic morphine
exposure in rodent models indicate significant µ-receptor
down-regulation, as well as decreased levels of receptor protein, in
both brain and spinal cord regions. We hypothesized that
combination-treated animals would show no receptor protein
down-regulation. The levels of opioid (µ,
,
) and cannabinoid
(CB1) receptor protein were evaluated in mouse models of short-term
exposure to
9-THC, morphine, or both drugs in
combination. Western blot analysis revealed that all three types of
opioid receptor protein are significantly decreased in
morphine-tolerant mouse midbrain. This down-regulation was not seen in
combination-treated animals. In the spinal cord, there was an
up-regulation of µ-,
-, and
-opioid receptor protein in
combination-treated mice when compared with morphine-tolerant mice.
There were no apparent changes in levels of CB1 receptor protein in
midbrain regions, and there was an up-regulation of CB1 protein
in the spinal cord. The data presented here indicate that there is a
correlation between morphine tolerance and receptor protein regulation.
A combination of
9-THC and morphine retains high
antinociceptive effect without causing changes in receptor protein that
may contribute to tolerance.
This article has been cited by other articles:
![]() |
L. J. Sim-Selley, N. S. Schechter, W. K. Rorrer, G. D. Dalton, J. Hernandez, B. R. Martin, and D. E. Selley Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration Mol. Pharmacol., September 1, 2006; 70(3): 986 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Jimenez, M. M. Puig, and O. Pol Antiexudative Effects of Opioids and Expression of {kappa}- and {delta}- Opioid Receptors during Intestinal Inflammation in Mice: Involvement of Nitric Oxide J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 261 - 270. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Wallace, R. E. Blair, K. W. Falenski, B. R. Martin, and R. J. DeLorenzo The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 129 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Pol, J. R. Palacio, and M. M. Puig The Expression of {delta}- and {kappa}-Opioid Receptor Is Enhanced during Intestinal Inflammation in Mice J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 455 - 462. [Abstract] [Full Text] [PDF] |
||||